In December 2007, the New York Times published an article entitled "Data about Zetia risk was not fully revealed." The article claimed that Merck and Schering-Plough, the manufacturers of Zetia (aka ezetimibe), have information pertaining to the risk of liver damage when taking this cholesterol lowering medication in combination with statin drugs but that the companies have not released them to the public. The 2 companies confirm that this information exists yet justify not publishing...